Henry Schein, Inc.

NasdaqGS:HSIC Lagerbericht

Marktkapitalisierung: US$8.3b

Henry Schein Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Henry Schein wird ein jährliches Gewinn- und Umsatzwachstum von 13.8% bzw. 3.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 13.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 15.7% betragen.

Wichtige Informationen

13.8%

Wachstumsrate der Gewinne

13.71%

EPS-Wachstumsrate

Healthcare Gewinnwachstum18.3%
Wachstumsrate der Einnahmen3.6%
Zukünftige Eigenkapitalrendite15.74%
Analystenabdeckung

Good

Zuletzt aktualisiert06 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Analyseartikel • May 08

Henry Schein, Inc. Just Recorded A 8.1% EPS Beat: Here's What Analysts Are Forecasting Next

Henry Schein, Inc. ( NASDAQ:HSIC ) shareholders are probably feeling a little disappointed, since its shares fell 5.5...
Analyseartikel • Aug 08

Henry Schein, Inc. Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next

NasdaqGS:HSIC 1 Year Share Price vs Fair Value Explore Henry Schein's Fair Values from the Community and select yours...

Recent updates

Analyseartikel • May 08

Henry Schein, Inc. Just Recorded A 8.1% EPS Beat: Here's What Analysts Are Forecasting Next

Henry Schein, Inc. ( NASDAQ:HSIC ) shareholders are probably feeling a little disappointed, since its shares fell 5.5...
Narrativ-Update • Apr 26

HSIC: Improving Dental Demand And Buybacks Are Expected To Support Upside

Narrative Update on Henry Schein The updated analyst price target for Henry Schein reflects a modest upward adjustment in fair value to about $90 per share, as analysts incorporate refreshed models following recent Q4 results, new initiations, and several target raises across the Street. Analyst Commentary Recent research updates on Henry Schein show a mixed but generally constructive tone, with several firms revising models after Q4 results and initial FY26 guidance.
Narrativ-Update • Apr 11

HSIC: Rising Dental Demand And New CEO Transition Are Expected To Support Upside

Henry Schein's updated analyst price target edges slightly lower to about $89, as analysts refine their models following recent Q4 results and revised long-term growth assumptions across the Street. Analyst Commentary Street research around Henry Schein has turned more constructive overall, with several firms updating models following the Q4 print and initial FY26 guidance.
Narrativ-Update • Mar 28

HSIC: Rising Dental Demand And New CEO Are Expected To Support Upside

Narrative Update on Henry Schein The updated analyst price target for Henry Schein edges up to $90.00, reflecting a series of target increases across the Street as analysts factor in better than expected Q4 results, initial FY26 guidance, refreshed models, and improved visibility on growth and end market demand. Analyst Commentary Street research on Henry Schein clusters around higher price targets following Q4 results and initial FY26 guidance, with most firms updating their models and a mix of Outperform, Overweight, Neutral, Hold, and Market Perform ratings.
Narrativ-Update • Mar 13

HSIC: Improving Dental Demand And New CEO Leadership Will Support Upside

The analyst price target for Henry Schein has been raised from $83.21 to $89.79, reflecting updated models that factor in Q4 results, initial FY26 guidance, and what analysts describe as better growth visibility and a more supportive demand backdrop. Analyst Commentary Across the Street, recent research points to a more constructive stance on Henry Schein following Q4 results and initial FY26 guidance, with several firms revising their models and resetting price targets.
Neues Narrativ • Feb 25

Cloud Software And Specialty Products Will Reshape This Healthcare Distributor’s Future Earnings Power

Catalysts About Henry Schein Henry Schein is a global distributor of dental and medical products and services with growing software, specialty and value-added solutions for healthcare providers. What are the underlying business or industry changes driving this perspective?
Narrativ-Update • Feb 25

HSIC: Steadier Dental Demand And CEO Transition Will Support Balanced Outlook

Analysts have nudged their fair value estimate for Henry Schein up from $78.14 to $83.21, citing higher Street price targets and commentary about steadier organic growth and improving dental demand as the main supports for the updated view. Analyst Commentary Recent Street research on Henry Schein leans constructive, with several firms lifting price targets and, in one case, upgrading the rating as sentiment around dental demand and organic growth improves.
Narrativ-Update • Feb 10

HSIC: Revised Assumptions And CEO Transition Will Support Balanced Earnings Outlook

Analysts have increased their price target on Henry Schein by US$7, citing updated assumptions around revenue growth, margins, and future P/E levels that contribute to a revised valuation view. Analyst Commentary Recent research behind the US$7 upward move in the price target focuses on refreshed assumptions for Henry Schein’s revenue trajectory, margin profile, and future P/E levels.
Narrativ-Update • Jan 25

HSIC: Q3 Beat And CEO Transition Will Support Range-Bound Earnings Momentum

Narrative Update: Henry Schein The analyst price target for Henry Schein has moved slightly higher by about US$0.50, as analysts point to recent price target increases and a "clean beat" in Q3 that they see as supporting a modestly higher fair value while still viewing the shares as range bound. Analyst Commentary Recent Street commentary on Henry Schein points to a mixed setup, with some bullish analysts nudging price targets higher on the back of Q3 execution and others still reluctant to see a clear path out of the stock's trading range.
Narrativ-Update • Jan 11

HSIC: Q3 Beat And AI Partnerships Will Support Range-Bound Earnings Momentum

Analysts have raised their price target on Henry Schein to US$75 from US$71, citing a clean Q3 earnings beat that they view as supporting the recent share price strength, while also questioning how much further the stock can advance beyond its recent trading range. Analyst Commentary Bullish Takeaways Bullish analysts view the Q3 result as a clean beat, which they see as supporting the recent share price move and giving the higher US$75 target some fundamental backing.
Narrativ-Update • Dec 19

HSIC: Q3 Beat And Buybacks Will Support Range-Bound Earnings Momentum

Analysts have modestly raised their price target on Henry Schein to approximately $75, reflecting a slightly higher fair value and future price-to-earnings multiple following a clean Q3 beat, even as they remain cautious about the stock meaningfully breaking out of its recent trading range. Analyst Commentary Street research following the Q3 report reflects a mix of cautious optimism and ongoing skepticism about Henry Schein's near term upside potential.
Seeking Alpha • Dec 05

Henry Schein Can Make Your Portfolio Smile

Summary Henry Schein stands out as the largest global provider of healthcare products and services for office-based dental and medical practitioners, with a strong market share. HSIC continues to deliver solid growth, reporting Q3 revenue up 5.2% year-over-year and improved profitability across all segments, driven by internal growth and targeted programs. Management anticipates ongoing revenue and EBITDA growth, supported by demographic trends, increased healthcare access, and technological advancements like AI in dental care. Shares are attractively valued relative to peers, justifying a soft "Buy" rating for this high-quality industry leader with promising expansion catalysts. Read the full article on Seeking Alpha
Narrativ-Update • Dec 05

HSIC: Q3 Beat And Capital Returns Will Support Measured Earnings Momentum

Analysts modestly raised their price target on Henry Schein to $75 from $71, citing a clean Q3 beat that supports recent share gains while still questioning the stock's ability to break out above its historically defined trading range. Analyst Commentary Analysts highlight that the latest quarter delivered a clean beat versus expectations, reinforcing confidence in Henry Schein's ability to execute on its operating plan despite macro and industry headwinds.
Narrativ-Update • Nov 20

HSIC: Operational Improvements and Automation Are Expected to Support Earnings Momentum

Analysts have increased their price target for Henry Schein from $75 to $77, citing expectations for moderate improvements in revenue growth and future earnings. They also pointed to optimism driven by recent operating performance and strategic initiatives.
Narrativ-Update • Nov 05

HSIC: Earnings Momentum From Automation And E-Commerce Will Shape Outlook

Henry Schein’s analyst price target has increased from $73.23 to $75.15 per share, reflecting analysts’ confidence in improving margins and strategic initiatives following recent earnings results. Analyst Commentary Following the company's recent performance and updated guidance, research analysts have issued new commentary highlighting both upward momentum and remaining concerns regarding Henry Schein's outlook.
Analyseartikel • Aug 08

Henry Schein, Inc. Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next

NasdaqGS:HSIC 1 Year Share Price vs Fair Value Explore Henry Schein's Fair Values from the Community and select yours...
Seeking Alpha • Mar 11

Henry Schein Looks Bullish (Technical Analysis)

Summary HSIC shows bullish price action, momentum, volume, and relative strength, making it an attractive investment with a 2.6 reward-to-risk ratio. The stock is in an uptrend, trading above its 30-week EMA, and has bullish short-term and long-term momentum as indicated by the PPO. Institutional buying supports bullish volume trends, and HSIC has been outperforming the S&P 500 since December 2024. Despite recent earnings not meeting expectations, future earnings and revenue growth, along with sector strength, indicate potential for price targets of $82.63 and $92.68. Read the full article on Seeking Alpha
Seeking Alpha • Mar 04

Henry Schein: An Industry Leader That Offers Some Upside From Here

Summary Henry Schein is the world's largest provider of healthcare products and services for office-based dental and medical practitioners, showing consistent growth through acquisitions. Despite a 3% dip in shares, management's 2025 guidance indicates continued growth, justifying a bullish stance on the stock. The firm reported a 5.8% revenue increase in Q4 2024, driven by organic growth and acquisitions, with significant improvements in net income and operating cash flow. Henry Schein's market leadership and strategic acquisitions across various healthcare segments make it a solid investment, warranting a soft 'buy' rating. Read the full article on Seeking Alpha
Seeking Alpha • Dec 10

Henry Schein: The Kind Of Business I Like But No Margin Of Safety Now

Summary Although the U.S. stock market is currently 6.9% overvalued, according to Morningstar's analysts as of December 6, 2024, there could be opportunities in undervalued sectors like healthcare. Henry Schein is a candidate surfaced by a screen in this sector. It has many characteristics that I like in companies: easy-to-understand business, and profitable, among many others. There are some short-term headwinds that investors must be aware of but not overly concerned about. No investment is so good that it is worth buying at any price, and that applies to Henry Schein, which is currently overvalued. Read the full article on Seeking Alpha
Seeking Alpha • Nov 20

Henry Schein: Another Day, Another Purchase

Summary Henry Schein announced the acquisition of Acentus, a small medical product supplier, to expand its homecare medical products platform despite recent underperformance in cash flow metrics. The CGM market, where Acentus operates, is expected to grow significantly, making the acquisition strategically sound, though financial benefits remain uncertain without disclosed terms. Despite revenue growth from acquisitions, Henry Schein's profitability metrics have declined, raising concerns about its ability to meet its revised 2024 revenue and profit targets. While Henry Schein shows potential for cost savings and slight undervaluation, persistent profitability issues and investor skepticism warrant only a cautious 'buy' rating, subject to future performance. Read the full article on Seeking Alpha
User avatar
Neues Narrativ • Aug 25

Critical Acquisitions And High-Growth Product Expansion Set To Transform Dental Giant

Expansion into high-growth products and strategic acquisitions aimed at increasing gross margins through improved integration and efficiency.
Seeking Alpha • May 23

Henry Schein: Acquisition Strategy Isn't Pulling Its Economic Weight

Summary Henry Schein, Inc. came in with flat revenue growth in Q1 FY'24, with most expansion coming from acquisitions. The company's capital allocation strategy, focused on acquisitions, is not creating economic value for shareholders in my view. Based on my analysis, the company's performance does not justify a higher valuation. Read the full article on Seeking Alpha

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:HSIC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202814,82958770587911
12/31/202714,26454364982915
12/31/202613,74748248862215
3/28/202613,384395391578N/A
12/27/202513,184398521712N/A
9/27/202512,938391356535N/A
6/28/202512,773389334512N/A
3/29/202512,669407508688N/A
12/28/202412,673390661848N/A
9/28/202412,499314421612N/A
6/29/202412,487352495692N/A
3/30/202412,451388473670N/A
12/30/202312,339416313500N/A
9/30/202312,693445587786N/A
7/1/202312,598458480653N/A
4/1/202312,528478387536N/A
12/31/202212,647538474602N/A
9/24/202212,607638528625N/A
6/25/202212,718650648738N/A
3/26/202212,655646656740N/A
12/25/202112,401631598710N/A
9/25/202112,236626723783N/A
6/26/202111,898606783833N/A
3/27/202110,615438544583N/A
12/26/202010,119403550599N/A
9/26/20209,622591477542N/A
6/27/20209,291585436512N/A
3/28/202010,054713683766N/A
12/28/20199,986701N/A654N/A
9/28/20199,789488N/A655N/A
6/29/20199,636444N/A597N/A
3/30/20199,504438N/A722N/A
12/29/20189,418431N/A685N/A
9/29/201810,263304N/A629N/A
6/30/201811,069352N/A586N/A
3/31/201811,812377N/A527N/A
12/30/20178,883293N/A546N/A
9/30/201712,264554N/A572N/A
7/1/201711,968550N/A619N/A
4/1/201711,782534N/A668N/A
12/31/201611,572507N/A643N/A
9/24/201611,302498N/A676N/A
6/25/201611,122492N/A605N/A
3/26/201610,879489N/A536N/A
12/26/201510,630479N/A616N/A
9/26/201510,481482N/A563N/A
6/27/201510,419469N/A630N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: HSICDas prognostizierte Gewinnwachstum (13.8% pro Jahr) liegt über der Sparquote (3.5%).

Ertrag vs. Markt: HSICDie Erträge des Unternehmens (13.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (16.7% pro Jahr).

Hohe Wachstumserträge: HSICDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: HSICDie Einnahmen des Unternehmens (3.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.7% pro Jahr).

Hohe Wachstumseinnahmen: HSICDie Einnahmen des Unternehmens (3.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: HSICDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (15.7%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/21 06:00
Aktienkurs zum Tagesende2026/05/21 00:00
Gewinne2026/03/28
Jährliche Einnahmen2025/12/27

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Henry Schein, Inc. wird von 33 Analysten beobachtet. 15 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Jeffrey JohnsonBaird
Lawrence MarshBarclays
Glen SantangeloBarclays